SITC Lung Cancer and Mesothelioma Immunotherapy Guideline

Published Guideline 

READ GUIDELINE

The Lung Cancer and Mesothelioma CPG originally published in JITC on May 31, 2022.

SITC continuously evaluates the field for practice-changing data and new FDA approvals. When needed, the Lung Cancer and Mesothelioma CPG Expert Panel will guide the development of updates within this CPG. Updates will appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.

Guideline Education

SITC is pleased to offer companion education resources in support of the lung cancer and mesothelioma CPG. These activities feature faculty comprised of the guideline Expert Panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios.  The education available features one-hour webinars that take a deeper look at the guideline recommendations and mini-module videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG, available free and on-demand.

Webinars:

• Practical Management Pearls for Immunotherapy for the Treatment of Lung Cancer and Mesothelioma
  • This one hour on-demand webinar features members of the guideline Expert Panel. These faculty members discuss how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.

• Case Studies in Immunotherapy for the Treatment of Lung Cancer and Mesothelioma
  • This one hour on-demand webinar features members of the guideline Expert Panel. These faculty members discuss case studies that illustrate execution of SITC guideline recommendations, as well as discussion on difficult topics related to case management. 

Mini-Modules:

• Immunotherapy for Lung Cancer in Challenging Populations
  • Features a case presentation on a patient with PD-L1 high lung cancer and brain metastases and a discussion of the timing of systemic immunotherapy with radiation therapy and the role of PD-L1 levels in determining treatment. Panelists also provide insights into risks and benefits associated with combination therapies of chemotherapy with immunotherapy and current clinical trials addressing these issues.

• Key Principles of Immune Related Adverse Events (irAEs)
  • Discussion of the mechanisms and management of adverse events associated with immunotherapy for lung cancer and mesothelioma. Topics include the mechanisms and kinetics underlying irAEs, the importance of understanding patient baseline activities prior to immunotherapy, and the Common Terminology Criteria for Adverse Events (CTCAE). Concludes with a discussion on the timing of initiating immune checkpoint blockade after chemoradiation for lung cancer.

• Managing Stage III Non-Small Cell Lung Cancer (NSCLC)
  • Features a case presentation on a patient with resectable stage IIIA NSCLC. Panelists discuss recent developments surrounding the treatment of resectable disease, including how tumor mutation status can inform treatment and the benefits associated with neoadjuvant immunotherapy. Also includes a review of treatment options for patients who do not achieve a pathologic complete response after neoadjuvant therapy and resection.